[Von Willebrand factor in coronary disease]

Arch Mal Coeur Vaiss. 1994 Jan;87(1):85-93.
[Article in French]

Abstract

The value of studying factors of haemostasis and thrombosis in patients with coronary artery disease is established. The endothelial lesion and evolution of the thrombus play key roles in acute coronary syndromes and coronary angioplasty. The von Willebrand factor (VWF) is known for its participation in primary haemostasis. Deficits of this factor lead to a haemorrhagic syndrome, von Willebrand's disease. This glycoprotein is mainly synthesised by the endothelial cells. Its polymeric composition allows identification of two types of multimeres. The high molecular weight, active multimeres are liberated from the endothelium after stimulation by thrombin. Low molecular weight multimeres are less active and are secreted continuously. The VWF promotes platelet adhesion and facilitates platelet aggregation. Experimental pig models with VWF deficiency show that this factor is essential for the constitution of an occlusive thrombus. Several physiopathological mechanisms interact to increase VWF concentrations during thrombosis: the endothelial lesion, adrenergic stimulation, acute phase reaction. Increased VWF concentrations have been reported in many clinical situations. The results are most demonstrative in coronary artery disease. The VWF is abnormally high from the time of hospital admission in patients with acute myocardial infarction and continues to increase up to the 5th day before falling, without returning to normal values, at the 15th day. It is a sensitive though not specific late diagnostic marker of myocardial infarction. Increased VWF concentrations are not proportional to the severity of coronary atherosclerosis. They are, however, related to the infarct size, to the inflammatory reaction and to the prothrombotic phase.(ABSTRACT TRUNCATED AT 250 WORDS)

Publication types

  • English Abstract
  • Review

MeSH terms

  • Angioplasty, Balloon, Coronary
  • Coronary Thrombosis / blood
  • Humans
  • Myocardial Ischemia / blood*
  • Myocardial Ischemia / complications
  • Myocardial Ischemia / therapy
  • Predictive Value of Tests
  • Risk Factors
  • Thrombolytic Therapy
  • von Willebrand Factor / analysis*
  • von Willebrand Factor / physiology

Substances

  • von Willebrand Factor